Chicago, ILNCT03932786Now EnrollingIRB Ready

Retinoblastoma Clinical Trial in Chicago, IL

Access cutting-edge retinoblastoma treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Vanderbilt-Ingram Cancer Center

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access retinoblastoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related retinoblastoma treatment provided free

Apply for This Chicago Location

Check if you qualify for this retinoblastoma clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Retinoblastoma Study in Chicago

This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma

Sponsor: Vanderbilt-Ingram Cancer Center

Who Can Participate

Inclusion Criteria

Unilateral or bilateral intraocular retinoblastoma
Diagnosis between the ages of 0 - 17.99 years
Diagnosis on or after January 1, 2008
No exclusions based on primary or secondary treatment modalities
Retrospective group patients must be ≥ 6 months post end of treatment at study entry
For those already at this timepoint, they are now eligible
For those in treatment, or otherwise not yet at this timepoint, they are eligible once at they are ≥ 6 months post end of treatment
Prospective group patients must not have begun treatment
Patients with diminished capacity will not be enrolled.
Language: Patients must be able to communicate in English, French, or Spanish
Sibling Cohort: One sibling, not affected by retinoblastoma will be enrolled, preference for the sibling closest in age to the RB patient.
Regulatory Requirements: All patients and/or their parents or legal guardians must sign a written informed consent. All institutional, FDA, and NCI requirements for human studies must be met.

Exclusion Criteria

based on primary or secondary treatment modalities
Retrospective group patients must be ≥ 6 months post end of treatment at study entry
For those already at this timepoint, they are now eligible
For those in treatment, or otherwise not yet at this timepoint, they are eligible once at they are ≥ 6 months post end of treatment
Prospective group patients must not have begun treatment
Patients with diminished capacity will not be enrolled.
Language: Patients must be able to communicate in English, French, or Spanish
Sibling Cohort: One sibling, not affected by retinoblastoma will be enrolled, preference for the sibling closest in age to the RB patient.
Regulatory Requirements: All patients and/or their parents or legal guardians must sign a written informed consent. All institutional, FDA, and NCI requirements for human studies must be met.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT03932786) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Retinoblastoma Treatment Options in Chicago, IL

If you're searching for retinoblastoma treatment options in Chicago, IL, this clinical trial (NCT03932786) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced retinoblastoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all retinoblastoma clinical trials near you to find additional studies recruiting in your area.

More Essential Tremor Trials in Chicago, IL

See all essential tremor clinical trials recruiting in Chicago — not just this study.

Browse Essential Tremor Trials in Chicago →

Browse More Trials by Condition

Essential Tremor TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL